Patent intelligence · US
US 9670484
Methods and compositions
Methods and compositions
Patent details — US 9670484
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 6, 2017
- Expiration
- Jun 1, 2037
- Applicant
- BICYCLE THERAPEUTICS LIMITED
- Claims
- 2
- CPC classes
- A61K, A61K47/54, A61K47/55, A61K47/64
Quick answer
US 9670484 (Methods and compositions) is held by BICYCLE THERAPEUTICS LIMITED. Status: granted. Granted Jun 6, 2017. Expires Jun 1, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BICYCLE THERAPEUTICS LIMITED
- Grant date
- Expiration
- Claims
- 2
- CPC classes
- A61K, A61K47/54, A61K47/55, A61K47/64
More from BICYCLE THERAPEUTICS LIMITED
Related pharmaceutical patents in our USPTO index.
-
US 12378288
Multimeric bicyclic peptide ligands
granted -
US 12377155
Bicyclic peptide ligands specific for PSMA
granted -
US 12350343
Bicyclic peptide ligands specific for MT1-MMP
granted -
US 12318454
Bicyclic peptide ligands specific for MT1-MMP
granted -
US 12150998
Bicyclic peptide ligands specific for P-selectin
granted -
US 12049520
Bicyclic peptide ligands specific for CD137
granted -
US 11970555
Bicyclic peptide ligands specific for transferrin receptor 1 (TfR1)
granted -
US 11970553
Heterotandem bicyclic peptide complex
granted
Frequently asked questions
What is US patent 9670484?
US 9670484 (Methods and compositions) is held by BICYCLE THERAPEUTICS LIMITED. Status: granted. Granted Jun 6, 2017. Expires Jun 1, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9670484?
BICYCLE THERAPEUTICS LIMITED is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 57 pharmaceutical patents for this assignee.
When does US 9670484 expire?
Our index shows an expiration date of Jun 1, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.